DEVELOPMENTAL RESEARCH PROGRAM

爱荷华大学/梅奥临床淋巴瘤孢子(UI/MC孢子)的发展目标 研究计划是支持创新的、科学合理的项目，这些项目调查与 转化性淋巴瘤研究。该计划在过去和现在的支持下非常成功 在过去的4年里，将有13个发展研究项目。其中三个项目已经收到 外部，同行评审的NCI资助或可资助的优先分数，3获得第二年资助，3 提供了对选定进行此次更新的主要研究项目有用的数据。这个 发展研究计划将提供高达50,000美元的一年(25,000美元来自UI/MC孢子 资金和来自机构资源的25,000美元)，每年向四个项目的每个项目提供 根据进展情况，有可能提供第二年的支助。预计对发展的支持 研究项目将继续产生新的假设，这些假设将在完整的用户界面/MC中进行测试 孢子赞助的项目或通过同行审查的外部赠款支助。中国的长期目标是 UI/MC孢子计划是将开发项目产生的结果转化为 淋巴瘤的发病率和死亡率。更具体地说，发展的目标 研究计划旨在：(1)鼓励与翻译相关的创新实验室、人口和 淋巴瘤和慢性淋巴细胞白血病的临床研究；(2)促进 淋巴瘤转化研究中的基础科学、人口科学和临床学科；以及，(3) 生成新的假设，以在大规模研究项目或临床试验中进行测试，这可能会导致 淋巴瘤发病率和死亡率显著降低。四项发展性研究概述 来自爱荷华大学和梅奥诊所的研究人员的项目包括在内，以证明 可应用于转化性淋巴瘤研究的正在进行的研究的深度和广度 并有资格获得UI/MC孢子开发计划支持。

The goal ofthe University of lowa / Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Developmental Research Program is to support innovative, scientifically sound projects that investigate a question pertaining to translational lymphoma research. This program was highly successful with past and current support over the past 4 years going to 13 developmental research projects. Three of these projects have received external, peer-reviewed NCI funding or a fundable priority score, 3 received a second year of funding, and 3 provided data that was instrumental for the major research projects selected for this renewal. The Developmental Research Program will provide up to $50,000 for one year ($25,000 from UI/MC SPORE funds and a matching $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress. It is anticipated that support of developmental research projects will continue to result in the generation of new hypotheses that will be tested in full UI/MC SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the UI/MC SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma. More specifically, the objectives ef the Developmental Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and clinical studies in lymphoma and chronic lymphocytic leukemia; (2) foster extensive collaboration between basic science, population science and clinical disciplines in translational research in lymphoma; and, (3) generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to significant reduction of lymphoma incidence and mortality. Brief outlines of four developmental research projects from investigators at the University of lowa and the Mayo Clinic are included to demonstrate the depth and breadth of ongoing research that can be applied to the translational lymphoma research at these institutions and could be eligible for UI/MC SPORE Developmental Program support.